<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545921</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-435</org_study_id>
    <secondary_id>2010-A00196-33</secondary_id>
    <nct_id>NCT01545921</nct_id>
  </id_info>
  <brief_title>Cancer End Of Life Evaluation</brief_title>
  <acronym>CEOLE</acronym>
  <official_title>Evaluation and Validation of Quality Of Life Scales in Palliative Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICO Paul Papin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICO Paul Papin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to culturally adapt and to validate Quality Of Life tools dedicated
      to the end of life for French cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      French clinical research in palliative care is confronted with a lack of tools allowing to
      estimate in a standardized way a patient related outcome. Scales used today are not
      specifically adapted to quality of life (QoL) at the end of life patient evaluation. So all
      the relative dimensions to this disease stage are not estimated. What establishes a brake in
      the improvement of a quality support.

      The dimensions of pain, psychological distress, fatigue, decrease of the autonomy are
      essential points estimated in &quot;classic&quot; questionnaires and frequently used at the palliative
      disease stage. However the end of life also recovers the domains of the spirituality,
      oneself's completion, relationship. These elements are essential to dread better QoL at end
      of life, but are not or do not little approach on the French questionnaires.

      The Missoula-Vitas Quality Of Life Index is a questionnaire developed by Byock, Merriman and
      Kinzbrunner and specifically designed for palliative situations [I. Byock, 1998]. This QoL
      tool provides an exhaustive assessment of important dimensions in this setting. The short
      version is composed of 15 items and asks patients to evaluate 5 dimensions: symptoms,
      function, interpersonal relationships, well-being and transcendence [I. Byock, 1998].

      Another tool, the QUAL-E, is longer with 25 items concerning 5 domains: life completion,
      relations with the health care system, preparation for end of life, symptom severity and
      affective social support [KE. Steinhauser, 2002]. However, these QoL tools have not been
      translated and adapted to French. Another concern is that the lack of specificity for cancer
      patients.

      The first step to improve evaluation of how French patients feel about this phase of their
      disease is to translate these specific end of life QoL tools. Assessing QoL at the end of
      life with dedicated tools could help to compare therapeutic strategies and could result in
      improvements in palliative care.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validation of QUALE and Missoula Vitas Quality Of Life Index (MVQOLI)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Both QUALE and MVQOLI have many questions, and each question is evaluated by a number of points. At the end of completion, a score is calculated thanks to number of points and is used to compare the different times completion :
no change of score between the 2 first completion (reproductibility)
change score with baseline
correlation with QLQ-C15 PAL Score
correlation with clinical measure (PS, PPS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life at different times</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Every month or more, QUALE, MVQOLI and QLQ-C15-PAL will be completed by patient, a final score will be calculated and compared at different times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spontaneous questionnaire completions</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>In arms C and D, patients can complete QLQ-C15-PAL and MVQOLI questionnaires at home if they need it. The number of spontaneous questionnaires completions will be evaluated and the impact on quality of life assessed thanks to calculated score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of completion</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Every month or more, the 3 questionnaires QUALE, MVQOLI and QLQ-C15-PAL have to be completed by patient. The rate of completion will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will complete QoL questionnaires in the following order :
MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will complete QoL questionnaires in the following order :
QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will complete QoL questionnaires in the following order :
MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will complete QoL questionnaires in the following order :
QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality Of Life questionnaires completion</intervention_name>
    <description>Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.
MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Palliative advanced cancer patient (Palliative chemotherapy, analgesic radiotherapy,
             surgery of comfort accepted).

          -  All cancer locations and cancer type

          -  Patient having the knowledge of their palliative disease stage.

          -  Patient follow-up at least once a month by a palliative caregiver.

          -  Age &gt; or = 18 years.

          -  Dated and signed consent.

          -  PS &gt; or = 2

          -  Life expectation &gt; or = 1 month.

        Exclusion Criteria:

          -  Psychiatric Disease or cognitive disorders disrupting the trial understanding and the
             enlightened and voluntary consent character.

          -  Patient who can not submit itself to the formal follow-up for psychological, social,
             family or geographical reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Commer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Berger, MD, PhD</last_name>
    <phone>33 2 41 35 27 34</phone>
    <email>virginie.berger@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessy Delaye, M Sc</last_name>
    <phone>33 2 41 35 29 31</phone>
    <email>jessy.delaye@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Le Pape, MD</last_name>
      <email>EmLepape@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie Le Pape, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Commer, MD</last_name>
      <email>jean-marie.commer@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie Commer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Faivre Chalon, MD</last_name>
      <email>didierfaivrechalon@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Régis Aubry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Guesdon, MD</last_name>
      <email>Guesdon@bergonie.org</email>
    </contact>
    <investigator>
      <last_name>Gérard Guesdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Heng Lam, MD</last_name>
      <email>you.lam@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>You Heng Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Favier, MD</last_name>
      <email>LFavier@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Laure Favier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Villet, MD</last_name>
      <email>s-villet@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Villet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Goineau, MD</last_name>
      <email>jgoineau@valdorel.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Goineau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Barrière, MD</last_name>
      <email>jerome.barriere@nice.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme Barrière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Toussaint Martel, MD</last_name>
      <email>s.toussaint@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Toussaint Martel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.centrepaulpapin.org/</url>
    <description>Sponsor Information</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality Of Life</keyword>
  <keyword>Cancer</keyword>
  <keyword>End of life</keyword>
  <keyword>palliative setting</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

